This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Carl C. Peck, MD; Robert J. Temple, MD; Jerry M. Collins, PhD
Food and Drug Administration Rockville, Md

JAMA. 1993;270(11):1317.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—It certainly may be, as Dr Alderman states, that one cannot generalize pharmacokinetic drug interactions by therapeutic class. Yet, the number of potential interactions that need to be assessed is daunting. Fortunately, in vitro methods can give guidance. Although there may not yet be enough experience to be sure that in vitro/in vivo correlation will regularly be present, the sertraline-fluoxetine experience (assuming that complete reports of the studies cited by Alderman, when published, support his description of them), where an in vitro difference appears to predict a clinical distinction, is an example of what can be accomplished. It should be appreciated, of course, that there are many properties of a drug besides its interactions that are pertinent to its benefits and risks, and that the practitioner needs to be aware of all of them to make intelligent treatment decisions.

Drs Gelfand and Lancaster point out an ironic consequence . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?